D Orazio & Associates Inc. Invests $245,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

D Orazio & Associates Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,924 shares of the biopharmaceutical company’s stock, valued at approximately $245,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Oppenheimer Asset Management Inc. boosted its position in shares of Gilead Sciences by 0.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock worth $15,441,000 after purchasing an additional 948 shares in the last quarter. Carrera Capital Advisors lifted its stake in shares of Gilead Sciences by 23.6% in the third quarter. Carrera Capital Advisors now owns 25,546 shares of the biopharmaceutical company’s stock valued at $2,142,000 after purchasing an additional 4,886 shares during the period. Aptus Capital Advisors LLC boosted its holdings in Gilead Sciences by 3.9% during the third quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 309 shares in the last quarter. Commonwealth Retirement Investments LLC grew its position in Gilead Sciences by 8.1% during the third quarter. Commonwealth Retirement Investments LLC now owns 24,510 shares of the biopharmaceutical company’s stock worth $2,055,000 after buying an additional 1,828 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Gilead Sciences by 1.9% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,023,984 shares of the biopharmaceutical company’s stock valued at $253,531,000 after buying an additional 55,841 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GILD. Oppenheimer boosted their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $91.50.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock worth $4,968,674 in the last ninety days. Insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Down 1.7 %

NASDAQ GILD traded down $1.57 during trading hours on Wednesday, hitting $92.78. 2,329,028 shares of the company’s stock were exchanged, compared to its average volume of 7,036,115. The business’s 50 day moving average is $85.95 and its 200-day moving average is $75.57. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.82 and a current ratio of 1.11. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm has a market capitalization of $115.51 billion, a P/E ratio of 1,048.33, a price-to-earnings-growth ratio of 3.01 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the firm posted $2.29 EPS. The company’s revenue was up 7.0% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.32%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.